Peer Exchange

Challenges in Treating Schizophrenia

Counseling Patients With Schizophrenia on Relapse

Schizophrenia Relapses and Patient Well-Being

Treatment Nonadherence and Schizophrenia Relapses

Socioeconomic Burden of Treatment Adherence in Schizophrenia

Psychosocial Interventions for Schizophrenia

Challenges With Oral Antipsychotics for Schizophrenia

Long-Acting Injectable Antipsychotics for Schizophrenia

Barriers to Prescribing LAIs for Schizophrenia

Misperceptions and Underutilization of LAIs for Schizophrenia

NCBH Guidelines and LAI Therapy for Schizophrenia

Advantages of LAI Antipsychotics for Schizophrenia

Dosing LAI Antipsychotics for Schizophrenia

Early Initiation of LAI Therapy for Schizophrenia

Current LAI Options for Schizophrenia

Second-Generation LAIs for Schizophrenia

LAI Treatment Selection and Patient Factors

Patient-Physician Collaboration and Schizophrenia Outcomes

Schizophrenia Treatment: Overcoming Obstacles

Schizophrenia Treatment and Outlook

Clinical Subtypes of ADHD

Factors That Predispose for ADHD

ADHD: Patient QOL and Misconceptions

What Prompts Patients to Seek an Evaluation for ADHD

Accurately Diagnosing ADHD

Challenges With Diagnosing ADHD

Non-Pharmacological Strategies for ADHD

Non-Stimulant Therapy for ADHD

Short- and Intermediate-Acting Stimulants for ADHD

Long-Acting Stimulants for ADHD

Prodrug Therapy for ADHD

Treatments for ADHD: Efficacy and Safety Data

Substance Abuse and ADHD

Adult ADHD Treatment Recommendations

Switching Medication for ADHD

Multimodal Treatment of ADHD

Novel Nonstimulant Therapy for ADHD

Exciting Therapies Under Investigation for ADHD

Treating ADHD: Current Unmet Needs

Managing ADHD During COVID-19

Evolution of Therapy and Destigmatizing ADHD

Pathological Differences Between Allergic Asthma and Nonallergic Asthma

Prevalence and Burden of Allergic Asthma

Treating Allergic Asthma During the Emergence of COVID-19

Role of Biomarkers in Allergic Asthma

Effect of Eosinophils on Treatment of Allergic Asthma

Response Biomarkers to Determine Efficiency in Treating Asthma

Novel Biomarkers for Biologic Targeted Mechanisms

Omalizumab in the Treatment of Allergic Asthma

IL-5 Inhibitors for the Treatment of Allergic Asthma

Dupilumab for Moderate to Severe Asthma

Personal Experience With Biologics When Treating Allergic Asthma

Role of Biologic Therapies in Improving Pulmonary Function

Safety Concerns With Biologics During the COVID-19 Pandemic

Final Thoughts on Allergic Asthma

Overview of Non-Radiographic Axial Spondyloarthritis

Misconceptions in Differentiating Nr-AxSpA and AS

Avoiding Misdiagnosis of Axial Spondyloarthritis

Disease Burden in Nr-AxSpA

Prevalence of nr-axSpA

Co-Manifestations in nr-axSpA

Additional Comorbidities in Nr-axSpA

Differential Diagnosis in Nr-axSpA

Patient Perspective: Signs and Symptoms of Nr-axSpA

Patient Diagnosis of Nr-axSpA

Diagnostic Workup of nr-AxSpA

Diagnosis of nr-AxSpA: X-Ray Imaging

Patient Perspective: Misdiagnosis of nr-axSpA

Accurately Diagnosing Nr-axSpA From Other Rheumatic Diseases

Progression of Nr-axSpA to Ankylosing Spondyloarthritis

Delayed Diagnosis of nr-axSpA

Treatment of Newly Diagnosed nr-axSpA

Treatment Strategies for nr-axSpA

C-AXSPAND Study in nr-axSpA

Management of nr-AxSpA: Emerging Agents and IFAA

Closing Thoughts on the Management of nr-AxSpA

Cardiac Amyloidosis Diagnostic Workup

Hypertrophic Cardiomyopathy Historical Prognosis

AL and ATTR Diagnosis: Echo and Noncardiac Biopsy

When Are Heart Biopsies Warranted?

Technetium Pyrophosphate Scan Benefits

Monoclonal Protein Testing and Wild-Type ATTR

Technetium Pyrophosphate Scan Prior to TAVR

AL and ATTR Survival Metrics

Poor Toleration: AL and ATTR Treatment Modification

Cardioversion and Atrial Fibrillation Ablation

Cardiac Amyloidosis: Pacemakers and Defibrillators

Therapy Selection for Congestive Heart Failure

Available ATTR Selective Stabilizers

Cardiomyopathy Management: NSAID Options

TTR Gene Silencers as Cardiomyopathy Treatment

Developing Agents for Cardiac Amyloidosis Management

Heart Failure & COVID-19: Mitigation Strategies

Heart Failure & COVID-19: Ensuring Best Practices

Burden of Heart Failure and Future Trends

Predisposing Risk Factors for Heart Failure

Gaps in Caring for Patients With Heart Failure

Evaluating and Diagnosing Heart Failure

Current Heart Failure Treatment Recommendations

Initiating/Switching Therapy for Heart Failure

2019 ACC Expert Consensus Decision Pathway for HF

Heart Failure: Frontline Treatment Decisions

Treatment for Heart Failure: Historical Overview

SGLT2 Inhibitors for Heart Failure

Learning More About SGLT2 Inhibitors for Heart Failure

Heart Failure: Applying Data Into Practice

Managing Heart Failure in the Community Setting

Trials of Interest in Heart Failure

SGLT2 Inhibitors: An Advance in Heart Failure

Heart Failure Management in the Current Era